Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen, a novel lipophilic peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC). Melflufen is in development as a new treatment for the hematological cancer multiple myeloma.
Audiocast regarding clinical program update
Oncopeptides held an audiocast April 24, where Jakob Lindberg, CEO, provided new guidance on the patient recruitment in the OCEAN study and a clinical program update. The audiocast was recorded.
Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. It belongs to the novel class Peptidase Enhanced Cytotoxics (PEnC), which is a family of lipophilic peptides that exhibit increased activity via peptidase cleavage and have the potential to treat many cancers.
Oncopeptides CEO Jakob Lindberg held a presentation at Jefferies 2018 Healthcare conference in London November 14. The presentation was also recorded as a webcast.
Melflufen (Ygalo®) is a peptide conjugated alkylator belonging to a novel class of peptidase-enhanced cytotoxics (PEnC), targets multiple myeloma (MM) cells with a unique mechanism of action.